Monte Rosa Therapeutics (GLUE) Other Working Capital Changes (2023 - 2025)
Historic Other Working Capital Changes for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $110.2 million.
- Monte Rosa Therapeutics' Other Working Capital Changes rose 129592.01% to $110.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 17231.82%. This contributed to the annual value of $83.4 million for FY2024, which is 6675.6% up from last year.
- Monte Rosa Therapeutics' Other Working Capital Changes amounted to $110.2 million in Q3 2025, which was up 129592.01% from -$23.0 million recorded in Q2 2025.
- Monte Rosa Therapeutics' 5-year Other Working Capital Changes high stood at $110.2 million for Q3 2025, and its period low was -$83.9 million during Q1 2025.
- In the last 3 years, Monte Rosa Therapeutics' Other Working Capital Changes had a median value of $2.3 million in 2024 and averaged $12.4 million.
- The largest annual percentage gain for Monte Rosa Therapeutics' Other Working Capital Changes in the last 5 years was 129592.01% (2025), contrasted with its biggest fall of 377031.05% (2025).
- Monte Rosa Therapeutics' Other Working Capital Changes (Quarter) stood at $40.0 million in 2023, then soared by 123.38% to $89.4 million in 2024, then rose by 23.35% to $110.2 million in 2025.
- Its last three reported values are $110.2 million in Q3 2025, -$23.0 million for Q2 2025, and -$83.9 million during Q1 2025.